ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 741

Cardiovascular Risk Re-Classification Using Carotid Ultrasound in Systemic Lupus Erythematosus Patients Is Related to the Damage Produced By the Disease

Juan Carlos Quevedo1, Iñigo Rúa-Figueroa2, Hiurma Sanchez-Perez3, Beatriz-Segura Tejera4, De Vera-González AM5, Alejandra Gonzalez-Delgado6 and Iván Ferraz-Amaro7, 1Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, 2Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, 3Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 4Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, 5Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, 6Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, 7Division of Rheumatology.Hospital Universitario de Canarias, Tenerife, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cardiovascular disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased in the prevalence of atherosclerosis. Composite scores of cardiovascular risk factors in patients with SLE have been found to underestimate cardiovascular risk. Besides, ultrasound of the carotid arteries has been proposed as a reclassification risk tool in inflammatory diseases. The main purpose of our study was to analyze the impact of ultrasound carotid assessment in the cardiovascular risk stratification of patients with SLE.

Methods: This cross-sectional study encompassed 276 SLE patients. Lipid profile, SCORE risk calculation, and disease activity (SLEDAI), severity (Katz), and damage (SLICC) indexes were assessed. Carotid intima-media thickness (cIMT) and carotid plaques were determined through ultrasound evaluation. Reclassification of SCORE after ultrasound carotid assessment was performed. A multivariable regression analysis, adjusted for classic cardiovascular related factors, was performed to evaluate how risk reclassification is influenced by disease characteristics in SLE patients and to describe potential predictors of this risk reclassification.

Results: Patients had a mean ± SD age of 51 ±12 years. The median SLE disease duration was 18 ± 10 years and SLICC and Katz indexes were, respectively, 1 (interquartile range –IQR- 0-2) and 2 (IQR 1-4). Thirty-four percent of the patients were categorized as having no activity based on the SLEDAI index, while 31%, 17%, and 8% were classified, respectively, in the mild, moderate, and high or very high categories. According to the SCORE risk stratification system, 184 (67%) and 73 (27%) patients were respectively in low and moderate categories. Additionally, only 16 (6%) patients were considered in high or very high risk categories. However, after carotid ultrasound assessment, 37% (100) of the patients were considered to be in the very high risk category. Exactly, 64 patients, 43 in both the low and moderate category, moved into very high category. Patients that experienced reclassification compared to those that did not were older (48 ± 11 vs. 57 ± 9 years, p=0.000) and had more hypertension (31 vs 56 %, p=0.000). Gender, BMI, waist circumference and the presence of dyslipidemia, smoking or diabetes did not shown differences. Lipid profile disclosed no differences between reclassified or non reclassified subjects. Disease duration was related to reclassification after multivariable analysis (OR 1.04 [95%CI 1.00-1.07], p=0.025). Similarly, a SLICC higher or equal to 1 (OR 2.48 (95%CI 1-15-5.34), p=0.020) and log SLICC (OR 1.63 (1.01-2.64), p=0.045) disclosed statically significant relation to reclassification after multivariable adjustment. These relations were also found when SLICC was used without the cardiovascular item that its contains although in the case of log SLICC the significant was not completely found (OR 1.56 (95%CI 0.95-2.64), p=0.077).

Conclusion: Reclassification into very high SCORE category is frequent after carotid ultrasound assessment in SLE patients. This reclassification can be independently explain by the damage produced by the disease and makes candidates for more intensive preventive interventions to one out of every three patients evaluated.


Disclosure: J. C. Quevedo, None; I. Rúa-Figueroa, None; H. Sanchez-Perez, None; B. S. Tejera, None; D. V. G. AM, None; A. Gonzalez-Delgado, None; I. Ferraz-Amaro, None.

To cite this abstract in AMA style:

Quevedo JC, Rúa-Figueroa I, Sanchez-Perez H, Tejera BS, AM DVG, Gonzalez-Delgado A, Ferraz-Amaro I. Cardiovascular Risk Re-Classification Using Carotid Ultrasound in Systemic Lupus Erythematosus Patients Is Related to the Damage Produced By the Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-risk-re-classification-using-carotid-ultrasound-in-systemic-lupus-erythematosus-patients-is-related-to-the-damage-produced-by-the-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-re-classification-using-carotid-ultrasound-in-systemic-lupus-erythematosus-patients-is-related-to-the-damage-produced-by-the-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology